PARP1 and ovarian carcinoma: In recent years, encouraging results have been achieved by PARP-1 inhibitors in treating BRCA 1/2-related breast and ovarian cancers [53, 54], and here we observed that a PARP-1 inhibitor also alleviates AML tumor load and prolongs survival in mice.